GNPX · Genprex, Inc.
Market Cap
$2.89M
Shares
819,709
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2024
Net Income
-$16.23M
+23.1%
FY2025
Operating Cash Flow
-$15.31M
+14.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 | $0 | |
| $9.82M | $9.43M | $10.54M | $17.62M | $11.51M | $8.97M | $7.3M | $1.97M | $971.43K | $289.93K | $354.88K | |
| $6.02M | $6.09M | $10.63M | $13.43M | $12.3M | $11.68M | $10.64M | $8.7M | $11.39M | $3.02M | $3.78M | |
| — | — | $773.48K | $0 | — | — | — | — | — | — | — | |
| $15.84M | $15.52M | $21.17M | $31.06M | $23.83M | $20.67M | $17.96M | $10.68M | $12.36M | $3.31M | $4.13M | |
| -$15.84M | -$15.52M | -$21.17M | -$31.06M | -$23.83M | -$20.67M | -$17.96M | -$10.68M | -$12.36M | -$3.31M | -$4.13M | |
| $30.58K | — | — | — | — | — | — | — | $37.98K | $1890 | $0 | |
| $18.78K | — | $63.57K | $215.11K | $90.1K | $5133 | $18.81K | $27.91K | $29.18K | $80 | $0 | |
| — | — | — | — | — | — | — | — | -$8798 | -$1810 | $0 | |
| — | $0 | $2650 | $0 | $0 | — | — | — | — | — | — | |
| -$16.5M | -$16.23M | -$21.11M | -$30.86M | -$23.74M | -$20.66M | -$17.94M | -$10.65M | -$12.37M | -$3.31M | -$4.13M | |
| — | -$16.23M | -$21.39M | -$30.86M | — | — | — | — | — | — | — | |
| USD/shares | $64.58 | -$382.80 | -$5,871.58 | -$24,816.00 | -$21,780.00 | -$19,360.00 | — | — | — | — | — |
| shares | — | 42.4K | 3642.6818 | 1243.4064 | 1089.8518 | 1070.3921 | 807.3381 | 364.2495 | 312.9777 | 261.3644 | 246.2428 |
| shares | — | — | — | — | — | 1070.3921 | 807.3381 | 364.2495 | 312.9777 | 261.3644 | 246.2428 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.02×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 128 similar-size Biotechnology companies (of 514 listed).
Key facts
CIK
1595248
CUSIP
372446401
13F (30d)
24 filings
24 filers
Visit website
Investor relations